Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 16Neoplasms 2Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Bulbo-Spinal Atrophy, X-Linked 1Adenocarcinoma 1

Interventions

Sorafenib 42lenvatinib 21Fluorouracil 16atezolizumab 15Oxaliplatin 14Bevacizumab 13Doxorubicin 12Radiosurgery 11Leucovorin 11Radiofrequency Ablation 10Ethiodized Oil 10pembrolizumab 7Folfox protocol 7sintilimab 6durvalumab 6Radiotherapy 6Nivolumab 6Epirubicin 6Cisplatin 6tremelimumab 5Gemcitabine 5apatinib 4Embolization, Therapeutic 4tislelizumab 3camrelizumab 3cabozantinib 3Tenofovir 3Pharmaceutical Preparations 3Mitomycin 3Magnetic Resonance Spectroscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Hepatocellular × abiraterone × Clear all
NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis

Phase 3 Not yet recruiting
5,000 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡